

Sheet 1 of 1Substitute Form PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
10278-009001Application No.  
09/407,605**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant  
Allan M. Miller et al.Filing Date  
September 28, 1999Group Art Unit  
1643**U.S. Patent Documents**

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

RECEIVED

OCT 17 2002

TECH CENTER 1600-2900

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
CHK	AG	96/09378 A1	03/28/1996	WIPO				
CHK	AH	98/12207 A1	03/26/1998	WIPO				
	AI							
	AJ							
	AK							

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
CHK	AL	Peter Lind et al., "Novel forms of B-domain-deleted recombinant factor VIII molecules Construction and biochemical characterization", <u>European Journal of Biochemistry</u> , Vol. 232, No. 1, pages 19-27 (August 15, 1995)
	AM	Carmel M. Lynch et al., "Sequences in the Coding Region of Clotting Factor VIII Act as Dominant Inhibitors of RNA Accumulation and Protein Production", <u>Human Gene Therapy</u> , Vol. 4, No. 3, pages 259-272 (June 1, 1993)
CHK	AN	Louise C. Wasley et al., "PACE Furin Can Process the Vitamin K-dependent Pro-factor IX Precursor within the Secretory Pathway", <u>Journal of Biological Chemistry</u> , Vol. 268, No. 12, pages 8458-8465 (April 25, 1993)
	AO	
	AP	

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)